Kitada Shuichi, Schulze P Christian, Jin Zhezhen, Clerkin Kevin, Homma Shunichi, Mancini Donna M
Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, New York, USA.
Department of Biostatistics, Mailman School of Public Health, Columbia University Medical Center, New York, New York, USA.
Int J Cardiol. 2016 Jan 15;203:929-935. doi: 10.1016/j.ijcard.2015.11.009. Epub 2015 Nov 9.
Placement of left ventricular assist devices (LVAD) as a bridge-to-heart transplantation (HTx) has rapidly expanded due to organ donor shortage. However, the timing of LVAD implantation is variable and it remains unclear if earlier implantation improves survival.
We analyzed 14,187 adult candidates from the United Network of Organ Sharing database. Patients were classified by 3 treatment strategies including patients medically treated alone (MED, n=11,009), patients on LVAD support at listing (Early-LVAD, n=1588) and patients undergoing LVAD placement while awaiting HTx (Delayed-LVAD, n=1590). Likelihood of HTx and event-free survival were assessed in patients subcategorized by clinical strategies and UNOS status at listing.
The device support strategy, despite the timing of placement, was not associated with increased likelihood of HTx compared to MED group. However, both LVAD implantation strategies showed better survival compared to MED group (Early-LVAD: HR 0.811 and 0.633, 95% CI 0.668-0.984 and 0.507-0.789, for 1A and 1B; p=0.034 and p<0.001, Delayed-LVAD: HR 0.553 and 0.696, 95% CI 0.415-0.736 and 0.571-0.847, for 1A and 1B; both p<0.001, respectively). Furthermore, there was no significant difference in survival between these LVAD implantation strategies in patients listed as 1B (p=0.500), although Early-LVAD implantation showed worse survival in patients listed as 1A (HR 1.467, 95% CI 1.076-2.000; p=0.015).
LVAD support strategies offer a safe bridge-to-HTx. Those candidates who receive urgent upfront LVAD implantation for HTx, and improve to 1B status, would achieve competitive survival with those who receive elective LVAD implantation.
由于器官供体短缺,作为心脏移植(HTx)过渡手段的左心室辅助装置(LVAD)植入术迅速增加。然而,LVAD植入的时机并不一致,早期植入是否能提高生存率仍不清楚。
我们分析了器官共享联合网络数据库中的14187名成年候选者。患者分为3种治疗策略,包括单纯药物治疗的患者(MED,n = 11009)、列入名单时接受LVAD支持的患者(早期LVAD,n = 1588)以及在等待HTx期间接受LVAD植入的患者(延迟LVAD,n = 1590)。根据临床策略和列入名单时的UNOS状态对患者进行亚分类,评估HTx的可能性和无事件生存率。
与MED组相比,无论植入时机如何,装置支持策略与HTx可能性增加无关。然而,与MED组相比,两种LVAD植入策略均显示出更好的生存率(早期LVAD:1A和1B的HR分别为0.811和0.633,95%CI为0.668 - 0.984和0.507 - 0.789;p = 0.034和p < 0.001,延迟LVAD:1A和1B的HR分别为0.553和0.696,95%CI为0.415 - 0.736和0.571 - 0.847;p均< 0.001)。此外,在列为1B的患者中,这些LVAD植入策略之间的生存率无显著差异(p = 0.500),尽管在列为1A的患者中,早期LVAD植入显示出较差的生存率(HR 1.467,95%CI 1.076 - 2.000;p = 0.015)。
LVAD支持策略为HTx提供了一个安全的过渡手段。那些因HTx而接受紧急前期LVAD植入并改善至1B状态的候选者,将与接受择期LVAD植入的患者获得具有竞争力的生存率。